9/28/2015 | PP | Alexza aims to conduct $5 million offering of 6% notes in two parts
|
10/27/2014 | PP | Alexza plans to conduct $8 million private placement of common shares
|
3/19/2014 | PP | Alexza Pharmaceuticals places $45 million 121/4% notes, issues warrants
|
3/19/2014 | PV | New Issue: Alexza Pharmaceuticals places $45 million 121/4% notes, issues warrants
|
7/23/2012 | PP | Alexza Pharmaceuticals inks $20 million stock purchase agreement
|
6/26/2012 | CVPF | Alexza Pharmaceuticals files $40 million stock, debt, preferreds shelf
|
2/17/2012 | PP | Alexza Pharmaceuticals prices $22 million public sale of equity units
|
2/16/2012 | PP | Alexza Pharmaceuticals to sell common stock through a public offer
|
5/3/2011 | PP | Alexza negotiates $16.1 million registered direct offering of units
|
8/5/2010 | PP | New Issue: Alexza plans $18.05 million registered direct offering of equity units
|
8/5/2010 | PP | Market Commentary: Alexza heralds registered deal; PetroLatina again taps market; 01 Communique gets growth funds
|
5/26/2010 | PP | New Issue: Alexza Pharmaceuticals heralds $25 million line of credit with Azimuth
|
5/5/2010 | PP | New Issue: Alexza secures $15 million loan from Hercules Technology for product commercialization
|
5/4/2010 | CVHYPF | Alexza Pharmaceuticals files $75 million stock, debt, preferreds shelf
|
9/30/2009 | PP | New Issue: Alexza plans to take in $19.72 million via private placement of shares
|
3/31/2008 | PP | New Issue: Alexza arranges $50 million committed equity financing facility
|
3/26/2008 | PP | New Issue: Alexza negotiates $10 million direct placement of stock, warrants
|
4/2/2007 | CV | Alexza Pharmaceuticals files $150 million shelf registration
|
11/14/2006 | BT | RBC reiterates Alexza at outperform
|
9/22/2006 | BT | Alexza begins phase 2a trial of AZ-004 in schizophrenic agitation
|
9/22/2006 | BT | Alexza at outperform by RBC
|
9/21/2006 | BT | JMP keeps Alexza at market outperform
|
8/11/2006 | BT | RBC reiterates Alexza at outperform
|
8/11/2006 | BT | Alexza reiterated at market outperform by JMP
|
6/26/2006 | BT | Alexza given outperform rating by RBC
|
6/6/2006 | BT | Alexza starts phase 2b trial of AZ-001 for migraine
|
5/18/2006 | BT | RBC quarterly biotechnology update
|
5/16/2006 | BT | JMP reiterates Alexza at market outperform
|
4/26/2006 | BT | Alexza starts AZ-003 phase 1 clinical trial
|
4/20/2006 | BT | Alexza starts phase 2a trial of AZ-002 in patients with panic disorder
|
4/18/2006 | BT | JMP rates Alexza at market outperform
|
3/27/2006 | BT | Alexza Pharmaceuticals greenshoe exercised in full, upping IPO to $50.6 million
|
3/8/2006 | BT | Market Commentary: Alexza IPO gets off; Cepheid off; Dyax deal seen; Elan, Biogen up; Neurocrine shakes off trial miss
|
3/8/2006 | BT | New Issue: Alexza raises $44 million in IPO at $8 per share - below range of $10 to $12
|
3/3/2006 | BT | Market Commentary: Angiotech to sell bonds, bank debt; Advanced Magnetics rises; Celgene on tear of new highs
|
2/15/2006 | BT | Alexza Pharmaceuticals sets talk at $10 to $12 per share for 5.5 million share IPO
|
12/22/2005 | BT | Alexza Pharmaceuticals files for $86.25 million IPO
|